To date, most of the clinical trials in systemic sclerosis (SSc) have been negative trials. One of the reasons for this may be that enrolled subjects are clinically heterogeneous and only a small subset of SSc patients respond to any one therapy. Better methods of classifying patients into clinically relevant subsets are needed. Multi-Analyte Profiling? (MAP) is cutting edge ELISA-based technology that determines levels of serum biomarkers in an unbiased manner by simultaneously measuring hundreds of analytes using small serum sample volumes. Preliminary studies using MAP suggest that there are differences In levels of serum proteins among SSc patients with or without pulmonary arterial hypertension;however, studies have been limited by sample sizes consisting of patients enrolled at a single center. The establishment of a Proteomics and Clinical Core as part of the larger PSO grant will fund the establishment of a linked SSc serum repository and clinical database. Applying MAP technology to hundreds of serum samples will permit identification of a smaller subset of proteins that reliably predicts disease phenotype in a cost-effective manner. This serum protein signature will be validated and will then be used In subsequent clinical trials to ensure that patients with similar disease phenotype are enrolled. The Proteomics and Clinical Core will address three specific aims namely 1) to establish a state-of-the-art electronic SSc patient registry and biorepository that contains serum samples from SSc patients and appropriate controls along with relevant clinical information that is collected using standardized approaches, 2) apply Multi-Analyte Profile? technology to 264 SSc and healthy control serum samples to discover and validate a small, core set of important SSc protein biomarkers. 3) work closely with the Bioinformatics Core to discover important associations between serum protein levels and clinical markers of SSc disease activity.

Public Health Relevance

Systemic sclerosis (SSc) is a clinically diverse disease. Preliminary studies testing new biomarkers, such as testing blood protein levels, suggest that levels differ amongst clinically distinct SSc patients. We propose to test blood samples from hundreds of patients for blood proteins to Identify a small set of blood markers that reliably predict distinct clinical subsets of patients.

National Institute of Health (NIH)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Center Core Grants (P30)
Project #
Application #
Study Section
Special Emphasis Panel (ZAR1-MLB)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Boston University
United States
Zip Code
Fan, Ming-Hui; Feghali-Bostwick, Carol A; Silver, Richard M (2014) Update on scleroderma-associated interstitial lung disease. Curr Opin Rheumatol 26:630-6
Farina, Antonella; Cirone, Mara; York, Michael et al. (2014) Epstein-Barr virus infection induces aberrant TLR activation pathway and fibroblast-myofibroblast conversion in scleroderma. J Invest Dermatol 134:954-64
Arron, Sarah T; Dimon, Michelle T; Li, Zhenghui et al. (2014) High Rhodotorula sequences in skin transcriptome of patients with diffuse systemic sclerosis. J Invest Dermatol 134:2138-45
Assassi, Shervin; Wu, Minghua; Tan, Filemon K et al. (2013) Skin gene expression correlates of severity of interstitial lung disease in systemic sclerosis. Arthritis Rheum 65:2917-27